View Older Stories View More Recent Stories
-
Citi on argenx SE (ARGX): 'We remain Buyers on today’s weakness'
-
argenx (ARGX) Weakness Said to be Tied to Negative FDA Report
-
TD Cowen on argenx SE (ARGX): 'Sjogren's Shows Multi-Billion Potential'
-
H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)
-
argenx (ARGX) Added to Wedbush Best Ideas List
-
Recent pullback offers an attractive buying opportunity in this stock: Citi
-
argenx SE (ARGX) PT Lowered to $699 at Citizens JMP
-
Baird Upgrades argenx SE (ARGX) to Outperform
-
argenx SE (ARGX:BB) (ARGX) PT Lowered to EUR525 at Deutsche Bank
-
TD Cowen on argenx SE (ARGX): 'We View the Selloff as a Buying Opportunity'
-
Leerink Partners on argenx SE (ARGX): 'Share Pullback Creates Buying Opp'ty'
-
argenx (ARGX) Tops Q1 EPS by 34c
-
TD Cowen Reiterates Buy Rating on argenx SE (ARGX)
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Stifel Reiterates Buy Rating on argenx SE (ARGX)
-
H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)
-
Guggenheim Reiterates Buy Rating on argenx SE (ARGX)
-
argenx (ARGX) announces FDA approval of VYVGART Hytrulo
-
Bernstein SocGen Group Double Upgrades argenx SE (ARGX:BB) (ARGX) to Outperform
-
TD Cowen Names argenx SE (ARGX) 'Europe Best Ideas'
-
Deutsche Bank Upgrades argenx SE (ARGX:BB) (ARGX) to Hold
-
argenx SE (ARGX) PT Raised to $1,100 at Guggenheim
-
argenx SE (ARGX) PT Raised to $720 at H.C. Wainwright
-
argenx SE (ARGX) PT Raised to $701 at Citizens JMP
-
argenx SE (ARGX) PT Raised to $761 at TD Cowen
-
argenx SE (ARGX) PT Raised to $717 at H.C. Wainwright
-
argenx SE (ARGX) PT Raised to $700 at Truist Securities
-
argenx SE (ARGX) PT Raised to $772 at Jefferies
-
argenx SE (ARGX) PT Raised to $725 at Piper Sandler Following New Neurologist Surveys
-
2025 Biopharma sector outlook
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Piper Sandler Reiterates Overweight Rating on argenx SE (ARGX) Following Investor Dinner
-
argenx SE (ARGX) PT Raised to $707 at Jefferies
-
argenx SE (ARGX) PT Raised to $675 at Oppenheimer
-
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR670 at Barclays
-
argenx SE (ARGX) PT Raised to $706 at Evercore ISI
-
Late Morning $5 Dip in argenx SE (ARGX) Attributed to Raymond James Comments, 'we are introducing the myositis opportunity into our model'
-
Wolfe Research Upgrades argenx SE (ARGX) to Outperform
-
Zai Lab Limited (ZLAB) and argenx (ARGX) Announce Approval of VYVGART Hytrulo
-
Scotiabank Upgrades argenx SE (ARGX) to Sector Outperform, 'Efgart Sales Going Strong'
-
argenx SE (ARGX:BB) (ARGX) PT Raised to EUR525 at Deutsche Bank
-
argenx SE (ARGX) PT Raised to $646 at Oppenheimer
-
argenx SE (ARGX) PT Raised to $620 at Piper Sandler
-
argenx SE (ARGX) PT Raised to $635 at Leerink Partners
-
argenx SE (ARGX) PT Raised to $617 at H.C. Wainwright
-
Baird Downgrades argenx SE (ARGX) to Neutral
-
William Blair Upgrades argenx SE (ARGX) to Outperform
-
Raymond James Reiterates Strong Buy Rating on argenx SE (ARGX)
-
argenx SE (ARGX) PT Raised to $660 at Truist Securities
-
argenx SE (ARGX) PT Raised to $707 at Stifel

